Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
NCT07743541
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Uterine Endometrial Cancer
Interventions
DRUG:
TUB-040 - Dose escalation
DRUG:
TUB-040 - RP2D
Sponsor
Gilead Sciences